227 related articles for article (PubMed ID: 22845402)
21. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
[TBL] [Abstract][Full Text] [Related]
22. Towards defining biomarkers indicating resistances to targeted therapies.
Stehle F; Schulz K; Seliger B
Biochim Biophys Acta; 2014 May; 1844(5):909-16. PubMed ID: 24269379
[TBL] [Abstract][Full Text] [Related]
23. Cancer Genetics and Implications for Clinical Management.
Jamieson NB; Chang DK; Biankin AV
Surg Clin North Am; 2015 Oct; 95(5):919-34. PubMed ID: 26315514
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.
Yauch RL; Settleman J
Curr Opin Genet Dev; 2012 Feb; 22(1):45-9. PubMed ID: 22321987
[TBL] [Abstract][Full Text] [Related]
25. Biomarker-Driven Treatments Yield Better Results.
Cancer Discov; 2016 Aug; 6(8):OF4. PubMed ID: 27357459
[TBL] [Abstract][Full Text] [Related]
26. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
27. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack.
Henderson D; Ogilvie LA; Hoyle N; Keilholz U; Lange B; Lehrach H;
Biotechnol J; 2014 Sep; 9(9):1104-14. PubMed ID: 25074435
[TBL] [Abstract][Full Text] [Related]
28. Circumventing cancer drug resistance in the era of personalized medicine.
Garraway LA; Jänne PA
Cancer Discov; 2012 Mar; 2(3):214-26. PubMed ID: 22585993
[TBL] [Abstract][Full Text] [Related]
29. Challenges in the Discovery of Novel Therapeutic Agents in Cancer.
Nagaraju GP; Kamal MA
Curr Drug Metab; 2019; 20(12):931-932. PubMed ID: 31989914
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
31. Toward precision medicine in glioblastoma: the promise and the challenges.
Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
[TBL] [Abstract][Full Text] [Related]
32. Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?
Cirkel GA; Gadellaa-van Hooijdonk CG; Koudijs MJ; Willems SM; Voest EE
Future Oncol; 2014 Feb; 10(3):417-28. PubMed ID: 24559448
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in clinical oncoproteomics.
Jain KK
J BUON; 2007 Sep; 12 Suppl 1():S31-8. PubMed ID: 17935275
[TBL] [Abstract][Full Text] [Related]
34. Meeting report: The international conference on tumor progression and therapeutic resistance.
El-Deiry WS
Cancer Res; 2005 Jun; 65(11):4475-84. PubMed ID: 15930261
[TBL] [Abstract][Full Text] [Related]
35. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference.
Tan DS; Gerlinger M; Teh BT; Swanton C
Eur J Cancer; 2010 Aug; 46(12):2166-77. PubMed ID: 20413300
[TBL] [Abstract][Full Text] [Related]
36. Prediction of individual response to anticancer therapy: historical and future perspectives.
Unger FT; Witte I; David KA
Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
[TBL] [Abstract][Full Text] [Related]
37. Using microarrays to predict resistance to chemotherapy in cancer patients.
Lee CH; Macgregor PF
Pharmacogenomics; 2004 Sep; 5(6):611-25. PubMed ID: 15335284
[TBL] [Abstract][Full Text] [Related]
38. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
39. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Wijdeven RH; Pang B; Assaraf YG; Neefjes J
Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
[TBL] [Abstract][Full Text] [Related]
40. Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.
Buck E; Mulvihill M; Iwata KK
Mt Sinai J Med; 2010; 77(4):358-65. PubMed ID: 20687181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
